We are excited to announce a $40 Million strategic investment from Sanofi Read more: https://lnkd.in/e94v3PiD
Vigil Neuroscience
Biotechnology Research
Watertown, MA 8,158 followers
Harnessing the power of microglia to transform treatments for neurodegenerative diseases
About us
Vigil Neuroscience is a clinical-stage biotechnology company focused on developing treatments for both rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel immune cells of the brain. We are utilizing the tools of modern neuroscience drug development across multiple therapeutic modalities in our efforts to develop precision-based therapies to improve the lives of patients and their families. VGL101, our lead clinical candidate, is a fully human monoclonal antibody agonist targeting human triggering receptor expressed on myeloid cells 2 (TREM2) in people with adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP), a rare and fatal neurodegenerative disease. We are also developing VG-3927, a novel small molecule TREM2 agonist, to treat common neurodegenerative diseases associated with microglial dysfunction, with an initial focus on Alzheimer’s disease (AD) in genetically defined subpopulations.
- Website
-
http://www.vigilneuro.com
External link for Vigil Neuroscience
- Industry
- Biotechnology Research
- Company size
- 51-200 employees
- Headquarters
- Watertown, MA
- Type
- Public Company
- Founded
- 2020
- Specialties
- neuroscience and microglia
Locations
-
Primary
Get directions
100 Forge Rd
Suite 700
Watertown, MA 02472, US
Employees at Vigil Neuroscience
Updates
-
Today signifies an important anniversary in American history and offers an opportunity to reflect on our shared history and our expectations for a future. We aim to amplify the voices of Black Americans & continue to push back against racial disparities in America and STEM. Learn more about racial inequities in scientific news coverage here: https://lnkd.in/e2uty-Bi In recognition of Juneteenth, the Vigil offices are closed #VigilantForYou
-
-
Tomorrow morning, management will present at the Goldman Sachs Annual Global Healthcare Conference in Miami. Learn more here: https://lnkd.in/gPSATNEh
-
-
This morning, Jennifer (Scutt) Ziolkowski and David Gray participated in a fireside chat at the Jefferies Global Healthcare Conference. Listen to the conversation here: https://lnkd.in/gPSATNEh
-
-
By targeting the brain’s natural immune cells, we aim to combine precision medicine with personalized medicine. Our CEO, Ivana Magovcevic-Liebisch, PhD, JD, recently wrote about our approach to neurodegeneration by targeting microglia. Learn more here: https://lnkd.in/eu9b25iy
Immuno-oncology brought incredible advancements to cancer treatments, and we plan to use microglia to do the same for neurological disorders. I recently wrote about the Vigil approach to neuro-immunology in Bruce Booth’s Life Sci VC blog. Read more here: https://lnkd.in/ecVxCQuD
-
The Vigil Team proudly honors #PrideMonth! If you are looking for opportunities for education, celebration, & empowerment, we encourage you to explore #Pride2024 events near you. For those in the Boston area, consider Boston Pride For The People’s parade on June 8: https://lnkd.in/e7s5UvVT #VigilantForYou
-
-
June marks the start of Alzheimer’s & Brain Awareness Month! This month serves as an opportunity to spread awareness & inspire progress in research and medicine. At Vigil, we work to develop transformative treatments for neurodegenerative disorders. Learn about VG-3927, our small molecule TREM2 agonist for the treatment of Alzheimer’s: https://lnkd.in/gC9XKPyr #VigilantForYou #ENDALZ
-
Vigil was one of the sponsors of the Museum of Science’s 2024 Stars of STEM event. Our team was thrilled to attend and support the mission of the MoS and spread the joy of science! Learn how the Museum of Science is inspiring a lifelong love of science: https://www.mos.org/about #LifeatVigil
-
-
Vigil Neuro is at #IAPRD2024! Our team is presenting details on the impact of misdiagnosis on the #ALSP patient journey & the importance of genetic testing. View our poster here: https://lnkd.in/ehND4SDz #HarnessingMicroglia
-
-
This week, the Vigil team is joining Alzheimer's Society’s annual campaign, Dementia Action Week. Join us in increasing public understanding of the many types of #dementia! It is important to understand the differences between “Dementia” & “Alzheimer’s Disease.” Dementia is a general term used to describe symptoms such as memory decline & #Alzheimer’s is the most common type of dementia. At Vigil, we are committed to developing treatment options for rare and common neurodegenerative diseases, such as Alzheimer’s. Learn more about our work: vigilneuro.com/ #VigilantForYou
-